PuSH - Publication Server of Helmholtz Zentrum München: High-dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Schnell, O.* ; Eisfelder, B.* ; Standl, E.* ; Ziegler, A.-G.*

High-dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM.

Diabetes 46, 1607-1011 (1997)

DOI

PMC

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

High-dose intravenous insulin infusion at the onset of IDDM has been suggested to improve beta-cell function during the 1st year of insulin treatment. To test this hypothesis, we randomly assigned newly diagnosed IDDM patients to receive either an experimental 2-week high-dose intravenous insulin infusion (n = 9; age, 25 +/- 7 years; HbA1e, 10.5 +/- 2.0%) or an intensive insulin therapy of four injections per day (n = 10; age, 28 +/- 7 years; HbA1c, 12.3 +/- 3.0%). The experimental-therapy group received three times more insulin (1.2 +/- 0.4 U.kg-1.day-1) than the intensive-therapy group (0.4 +/- 0.1 U.kg-1. day-1, P < 0.0005). By week 3, both groups were treated similarly with intensive insulin therapy and were followed for 1 year. beta-cell function was evaluated with fasting plasma C-peptide and glucagon-stimulated and mixed meal-stimulated C-peptide concentrations. In both groups, insulin doses were comparable, and HbA1c levels were near normal during follow-up. At diagnosis of IDDM, fasting C-peptide was 0.40 +/- 0.13 nmol/l in the experimental-therapy group and 0.39 +/- 0.23 nmol/l in the intensive-therapy group. Irrespective of treatment, a slight decline of fasting C-peptide was observed in sequential measurements up to 12 months in both groups (delta, -0.13 and -0.08 nmol/l, respectively; NS). Glucagon-stimulated C-peptide concentrations decreased from 0.54 +/- 0.18 and 0.70 +/- 0.39 nmol/l at month 0 to 0.41 +/- 0.20 and 0.61 +/- 0.52 nmol/l, respectively, at month 12. In the experimental-therapy group, mixed meal-stimulated C-peptide concentrations (area under the curve over 2 h) increased from 82.10 +/- 43.72 to 101.20 +/- 32.53 nmol/l and in the intensive-therapy group, from 75.05 +/- 46.01 to 107.20 +/- 102.51 nmol/l. Changes in stimulated C-peptide concentrations between month 0 and 12 were not significant in both groups. During follow-up, fasting and stimulated C-peptide concentrations were not significantly different between the experimental-therapy group and the intensive-therapy group. We conclude that as initial treatments of newly diagnosed IDDM, high-dose intravenous insulin infusion and intensive insulin therapy equally preserve beta-cell function during the 1st year of insulin therapy.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

0.000